Rigel Pharmaceuticals, Inc. · NASDAQ:RIGL
Schorno Dean L exercised options for 3,381 Rigel Pharmaceuticals, Inc. shares (Form 4)
Traded Jun 1, 2026 · Filed Jun 3, 2026
On Jun 1, 2026, Schorno Dean L (EVP & Chief Financial Officer) exercised options for 3,381 Rigel Pharmaceuticals, Inc. shares at an average US$14.83 for US$50,139, leaving 78,790 shares. Filed Jun 3, 2026 (Form 4).
- Options exercised
- 3,381 shares
- Price
- US$14.83 average (US$12.70 to US$18.70)
- Value
- US$50,139
- Holding after
- 78,790 shares
- Trading plan
- No
- Role
- EVP & Chief Financial Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Common Stock | Option exercise | 1,200 | US$18.70 | 77,537 | Direct |
| Jun 1, 2026 | Common Stock | Option exercise | 2,181 | US$12.70 | 79,718 | Direct |
| Jun 1, 2026 | Common Stock | Shares withheld for tax | 928 | US$29.86 | 78,790 | Direct |
Source
Related
- Rigel Pharmaceuticals, Inc.
- Schorno Dean L
- Rigel Pharmaceuticals, Inc. shareholders
- Form 4 · Schorno Dean L · Sep 3, 2026
- Form 4 · Santos David A · Sep 3, 2026
- Form 4 · Rodriguez Raul R · Sep 3, 2026
- Form 4 · Furey Raymond J. · Sep 3, 2026
- Schedule 13G/A · Armistice Capital, LLC · Aug 14, 2026
- Schedule 13G/A · Soleus Capital Master Fund, L.P. · Aug 13, 2026